Department of Internal Medicine/Cardiology, University of Leipzig-Heart Center, Germany.
J Am Coll Cardiol. 2011 Feb 1;57(5):538-45. doi: 10.1016/j.jacc.2010.09.038.
The purpose of this randomized study was to compare sirolimus-eluting stenting with coronary artery bypass grafting (CABG) for patients with unprotected left main (ULM) coronary artery disease.
CABG is considered the standard of care for treatment of ULM. Improvements in percutaneous coronary intervention (PCI) with use of drug-eluting stents might lead to similar results. The effectiveness of drug-eluting stenting versus surgery has not been established in a randomized trial.
In this prospective, multicenter, randomized trial, 201 patients with ULM disease were randomly assigned to undergo sirolimus-eluting stenting (n = 100) or CABG using predominantly arterial grafts (n = 101). The primary clinical end point was noninferiority in freedom from major adverse cardiac events, such as cardiac death, myocardial infarction, and the need for target vessel revascularization within 12 months.
The combined primary end point was reached in 13.9% of patients after surgery, as opposed to 19.0% after PCI (p = 0.19 for noninferiority). The combined rates for death and myocardial infarction were comparable (surgery, 7.9% vs. stenting, 5.0%; noninferiority p < 0.001), but stenting was inferior to surgery for repeat revascularization (5.9% vs. 14.0%; noninferiority p = 0.35). Perioperative complications including 2 strokes were higher after surgery (4% vs. 30%; p < 0.001). Freedom from angina was similar between groups (p = 0.33).
In patients with ULM stenosis, PCI with sirolimus-eluting stents did not show noninferiority [corrected] to CABG at 12-month follow-up with respect to freedom from major adverse cardiac events, which is mainly influenced by repeated revascularization, whereas for hard endpoints, [corrected] PCI results are favorable. A longer follow-up is warranted. [corrected]
本随机研究的目的是比较雷帕霉素洗脱支架置入术与冠状动脉旁路移植术(CABG)治疗无保护左主干(ULM)冠状动脉疾病的效果。
CABG 被认为是治疗 ULM 的标准方法。经皮冠状动脉介入治疗(PCI)中药物洗脱支架的应用的改善可能会带来类似的效果。药物洗脱支架置入术与手术的疗效尚未在随机试验中得到证实。
在这项前瞻性、多中心、随机试验中,201 例 ULM 疾病患者被随机分为雷帕霉素洗脱支架置入术(n=100)或主要采用动脉移植物的 CABG(n=101)组。主要临床终点是非劣效性,即 12 个月内无主要不良心脏事件,如心脏死亡、心肌梗死和靶血管血运重建的需求。
手术组的综合主要终点发生率为 13.9%,而 PCI 组为 19.0%(非劣效性 p=0.19)。死亡率和心肌梗死的综合发生率相似(手术组 7.9%,支架置入组 5.0%;非劣效性 p<0.001),但支架置入组再次血运重建的发生率高于手术组(5.9% vs. 14.0%;非劣效性 p=0.35)。手术组的围手术期并发症包括 2 例脑卒中发生率更高(4% vs. 30%;p<0.001)。两组间的心绞痛缓解率相似(p=0.33)。
在 ULM 狭窄患者中,与 CABG 相比,雷帕霉素洗脱支架 PCI 在 12 个月随访时并未显示出非劣效性,主要受到再次血运重建的影响,而对于硬终点,PCI 的结果是有利的。需要更长时间的随访。